<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03269591</url>
  </required_header>
  <id_info>
    <org_study_id>dr ghada</org_study_id>
    <nct_id>NCT03269591</nct_id>
  </id_info>
  <brief_title>Electromagnetic Field Versus Diclofenac Drugs on Primary Dysmenorrhea</brief_title>
  <acronym>magnetic</acronym>
  <official_title>Electromagnetic Field Versus Diclofenac Drugs on Primary Dysmenorrhea: Arandomized Controlled Trial in the Egyptian Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electromagnetic field versus diclofenac drugs on primary dysmenorrhea: Arandomized controlled
      trial in the Egyptian women
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Primary dysmenorrhea is one of the most common complaints of women and is also
      the most common gynecological problem worldwide. These cramps are recurrent and 90%
      adolescent girls and about 50% women suffer from it. Purpose of the study: to determine which
      is more effective in alleviating primary dysmenorrhea; pulsed electromagnetic field or
      diclofenac drugs. Methodology: The study was a randomized, double-blinded trial, fifty adult
      females participated in this study, were divided randomly into two groups equal in numbers:
      group (A) received pulsed electromagnetic field applied on pelvic region, 3 times per week
      for 3 months, 20 minutes per day and group (B) received diclofenac tablets, 50 mg only with
      onset of menstrual pain. All participants in both groups (A and B) were assessed pre- and
      post-treatment through measuring progesterone level in the blood, assessment of pain using
      visual analogue scale and physical as well as psychological symptoms by using menstrual
      symptom questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">October 29, 2016</completion_date>
  <primary_completion_date type="Actual">September 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>(Participant, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue scale</measure>
    <time_frame>three months</time_frame>
    <description>was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month); in both groups (A and B) by (16), it is a graphic rating scale with numerical values placed equidistantly along the line. The descriptors and numbers help the subject to place her estimate on line in which (0) mean no pain, (1) equal mild pain, (2) equal moderate pain, (3) mean severe pain and (4) mean unbearable pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progesterone blood level</measure>
    <time_frame>three months</time_frame>
    <description>Sample of blood was taken to detect the level of progesterone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual symptom questionnaire</measure>
    <time_frame>three months</time_frame>
    <description>to assess symptoms of dysmenorrhea</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Electromagnetic Field</condition>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Pulsed electromagnetic field</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>magnetic therapy device which generate frequency from 5-100 Hz and intensity from 1 to 60 Gauss. Group (A) received 20 min 3 times per week for three month with strength 60 gauss and frequency 50 Hz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diclofenac tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(50 mg) few hours at the onset of menstruation for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Visual analogue scale</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone blood level</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sample of blood was taken to detect the level of progesterone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menstrual symptom questionnaire</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>to assess symptoms of dysmenorrhea.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulsed electromagnetic field</intervention_name>
    <description>EASY Qs portable (by ASA, Italy)</description>
    <arm_group_label>Pulsed electromagnetic field</arm_group_label>
    <arm_group_label>diclofenac tablets</arm_group_label>
    <arm_group_label>Visual analogue scale</arm_group_label>
    <arm_group_label>Progesterone blood level</arm_group_label>
    <arm_group_label>Menstrual symptom questionnaire</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac tablets</intervention_name>
    <description>drugs</description>
    <arm_group_label>Pulsed electromagnetic field</arm_group_label>
    <arm_group_label>diclofenac tablets</arm_group_label>
    <arm_group_label>Visual analogue scale</arm_group_label>
    <arm_group_label>Progesterone blood level</arm_group_label>
    <arm_group_label>Menstrual symptom questionnaire</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Visual analogue scale</intervention_name>
    <description>a graphic rating scale</description>
    <arm_group_label>Pulsed electromagnetic field</arm_group_label>
    <arm_group_label>diclofenac tablets</arm_group_label>
    <arm_group_label>Visual analogue scale</arm_group_label>
    <arm_group_label>Progesterone blood level</arm_group_label>
    <arm_group_label>Menstrual symptom questionnaire</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Progesterone blood level</intervention_name>
    <description>blood test</description>
    <arm_group_label>Pulsed electromagnetic field</arm_group_label>
    <arm_group_label>diclofenac tablets</arm_group_label>
    <arm_group_label>Visual analogue scale</arm_group_label>
    <arm_group_label>Progesterone blood level</arm_group_label>
    <arm_group_label>Menstrual symptom questionnaire</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Menstrual symptom questionnaire</intervention_name>
    <description>questionnaire</description>
    <arm_group_label>Pulsed electromagnetic field</arm_group_label>
    <arm_group_label>diclofenac tablets</arm_group_label>
    <arm_group_label>Visual analogue scale</arm_group_label>
    <arm_group_label>Progesterone blood level</arm_group_label>
    <arm_group_label>Menstrual symptom questionnaire</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -regular menstrual cycle 21-35 days lasting 3-7 days

        Exclusion Criteria:

          -  Irregulars or infrequent menstrual cycles, Pacemaker, Myasthenia gravis,
             hyperthyroidism, active tuberculosis and psychosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>females</gender_description>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ghada Ebrahim El Refaye</investigator_full_name>
    <investigator_title>Clinical lecturer</investigator_title>
  </responsible_party>
  <keyword>Dysmenorrhea</keyword>
  <keyword>Pulsed electromagnetic field</keyword>
  <keyword>Diclofenac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Electromagnetic field versus diclofenac drugs on primary dysmenorrhea: Arandomized controlled trial in the Egyptian women</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

